MET and hepatocellular carcinoma: The model suggested that the interaction of MET with integrin α5β1 contributes to resistance mechanisms attributed to HGF signalling and that co-treatment of HCC cell lines with α5β1 inhibitor and RTK inhibitors inhibit the intracellular signalling response in a synergistic manner.